Vir Biotechnology (NASDAQ:VIR) PT Lowered to $41.00

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price decreased by equities researchers at Barclays from $59.00 to $41.00 in a research report issued to clients and investors on Friday, FlyOnTheWall reports. Barclays‘s price target points to a potential upside of 222.83% from the company’s current price. A number of other equities research […]

Related Keywords

Alaska ,United States ,China ,Canada , ,Needham Company ,Alaska Department Of Revenue ,China Universal Asset Management Co ,Morgan Stanley ,Vir Biotechnology Inc ,Commonwealth Equity Services ,Endurance Cayman Ltd Svf ,Nasdaq ,Royal Bank ,Summerhaven Investment Management ,Barclays ,Vir Biotechnology ,Get Free Report ,Biotechnology Trading Down ,Ltd Svf ,Haven Investment Management ,Universal Asset Management ,Alaska Department ,Equity Services ,Vir Biotechnology Daily ,Nasdaq Vir ,Ivir ,Medical ,Lower Price Target ,Barclays Plc ,